Urinary Biomarkers for the Noninvasive Detection of Gastric Cancer |
Li, Dehong
(Gansu Provincial Clinical Research Center for Laboratory Medicine)
Yan, Li (Gansu Provincial Clinical Research Center for Laboratory Medicine) Lin, Fugui (Gansu Provincial Clinical Research Center for Laboratory Medicine) Yuan, Xiumei (Gansu Provincial Clinical Research Center for Laboratory Medicine) Yang, Xingwen (Gansu Provincial Clinical Research Center for Laboratory Medicine) Yang, Xiaoyan (Gansu Provincial Clinical Research Center for Laboratory Medicine) Wei, Lianhua (Gansu Provincial Clinical Research Center for Laboratory Medicine) Yang, Yang (Gansu Provincial Clinical Research Center for Laboratory Medicine) Lu, Yan (Gansu Provincial Clinical Research Center for Laboratory Medicine) |
1 | Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 2016;30:836-848. DOI |
2 | Naito Y, Yoshioka Y, Yamamoto Y, Ochiya T. How cancer cells dictate their microenvironment: present roles of extracellular vesicles. Cell Mol Life Sci 2017;74:697-713. DOI |
3 | Huang T, Song C, Zheng L, Xia L, Li Y, Zhou Y. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy. Mol Cancer 2019;18:62. |
4 | Park JY, Kang CS, Seo HC, Shin JC, Kym SM, Park YS, et al. Bacteria-derived extracellular vesicles in urine as a novel biomarker for gastric cancer: integration of liquid biopsy and metagenome analysis. Cancers (Basel) 2021;13:4687. DOI |
5 | Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer 2019;18:75. |
6 | Qian X, Xie F, Wei H, Cui D. Identification of key circulating exosomal microRNAs in gastric cancer. Front Oncol 2021;11:693360. DOI |
7 | Dong X, Wang G, Zhang G, Ni Z, Suo J, Cui J, et al. The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer. Diagn Pathol 2013;8:45. DOI |
8 | Hong CS, Cui J, Ni Z, Su Y, Puett D, Li F, et al. A computational method for prediction of excretory proteins and application to identification of gastric cancer markers in urine. PLoS One 2011;6:e16875. DOI |
9 | Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011;278:28-45. DOI |
10 | Siddhartha R, Garg M. Molecular and clinical insights of matrix metalloproteinases into cancer spread and potential therapeutic interventions. Toxicol Appl Pharmacol 2021;426:115593. DOI |
11 | Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-573. DOI |
12 | Alaseem A, Alhazzani K, Dondapati P, Alobid S, Bishayee A, Rathinavelu A. Matrix metalloproteinases: a challenging paradigm of cancer management. Semin Cancer Biol 2019;56:100-115. DOI |
13 | Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006;312:608-622. DOI |
14 | Shimura T, Dagher A, Sachdev M, Ebi M, Yamada T, Yamada T, et al. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila) 2015;8:240-248. DOI |
15 | Trams EG, Lauter CJ, Salem N Jr, Heine U. Exfoliation of membrane ecto-enzymes in the form of microvesicles. Biochim Biophys Acta 1981;645:63-70. DOI |
16 | Wood SL, Knowles MA, Thompson D, Selby PJ, Banks RE. Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol 2013;10:206-218. DOI |
17 | Bax C, Lotesoriere BJ, Sironi S, Capelli L. Review and comparison of cancer biomarker trends in urine as a basis for new diagnostic pathways. Cancers (Basel) 2019;11:1244. DOI |
18 | Tan J, Qin F, Yuan J. Current applications of artificial intelligence combined with urine detection in disease diagnosis and treatment. Transl Androl Urol 2021;10:1769-1779. DOI |
19 | Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, et al. Mechanisms of nuclear content loading to exosomes. Sci Adv 2019;5:eaax8849. DOI |
20 | Wu J, Gao Y. Physiological conditions can be reflected in human urine proteome and metabolome. Expert Rev Proteomics 2015;12:623-636. DOI |
21 | Harpole M, Davis J, Espina V. Current state of the art for enhancing urine biomarker discovery. Expert Rev Proteomics 2016;13:609-626. DOI |
22 | Albalat A, Mischak H, Mullen W. Clinical application of urinary proteomics/peptidomics. Expert Rev Proteomics 2011;8:615-629. DOI |
23 | Shao C, Wang Y, Gao Y. Applications of urinary proteomics in biomarker discovery. Sci China Life Sci 2011;54:409-417. DOI |
24 | Shimura T, Dayde D, Wang H, Okuda Y, Iwasaki H, Ebi M, et al. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br J Cancer 2020;123:1656-1664. DOI |
25 | Herrera C, Escalante T, Rucavado A, Fox JW, Gutierrez JM. Metalloproteinases in disease: identification of biomarkers of tissue damage through proteomics. Expert Rev Proteomics 2018;15:967-982. DOI |
26 | Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34:D140-D144. DOI |
27 | Sun IO, Lerman LO. Urinary microRNA in kidney disease: utility and roles. Am J Physiol Renal Physiol 2019;316:F785-F793. DOI |
28 | Armitage EG, Barbas C. Metabolomics in cancer biomarker discovery: current trends and future perspectives. J Pharm Biomed Anal 2014;87:1-11. DOI |
29 | Pejcic M, Stojnev S, Stefanovic V. Urinary proteomics--a tool for biomarker discovery. Ren Fail 2010;32:259-268. DOI |
30 | Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004;1:47-53. DOI |
31 | Iwasaki H, Shimura T, Yamada T, Okuda Y, Natsume M, Kitagawa M, et al. A novel urinary microRNA biomarker panel for detecting gastric cancer. J Gastroenterol 2019;54:1061-1069. DOI |
32 | Dinges SS, Hohm A, Vandergrift LA, Nowak J, Habbel P, Kaltashov IA, et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Nat Rev Urol 2019;16:339-362. DOI |
33 | Couzin J. Breakthrough of the year. Small RNAs make big splash. Science 2002;298:2296-2297. DOI |
34 | Zhang T, Watson DG, Wang L, Abbas M, Murdoch L, Bashford L, et al. Application of holistic liquid chromatography-high resolution mass spectrometry based urinary metabolomics for prostate cancer detection and biomarker discovery. PLoS One 2013;8:e65880. DOI |
35 | Huang R, Shen K, He Q, Hu Y, Sun C, Guo C, et al. Metabolic profiling of urinary chiral amino-containing biomarkers for gastric cancer using a sensitive chiral chlorine-labeled probe by HPLC-MS/MS. J Proteome Res 2021;20:3952-3962. DOI |
36 | Chen Y, Zhang J, Guo L, Liu L, Wen J, Xu L, et al. A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis. Oncotarget 2016;7:87496-87510. DOI |
37 | Patel S, Ahmed S. Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. J Pharm Biomed Anal 2015;107:63-74. DOI |
38 | Burton C, Ma Y. Current trends in cancer biomarker discovery using urinary metabolomics: achievements and new challenges. Curr Med Chem 2019;26:5-28. DOI |
39 | Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-1741. DOI |
40 | Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res 2004;32:D109-D111. DOI |
41 | Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 2012;41:1871-1878. DOI |
42 | Biscontin A, Casara S, Cagnin S, Tombolan L, Rosolen A, Lanfranchi G, et al. New miRNA labeling method for bead-based quantification. BMC Mol Biol 2010;11:44. DOI |
43 | Meng Y, Eirin A, Zhu XY, Tang H, Chanana P, Lerman A, et al. The metabolic syndrome alters the miRNA signature of porcine adipose tissue-derived mesenchymal stem cells. Cytometry A 2018;93:93-103. DOI |
44 | Hung PS, Chen CY, Chen WT, Kuo CY, Fang WL, Huang KH, et al. miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma. PLoS One 2017;12:e0177346. DOI |
45 | Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008;455:1054-1056. DOI |
46 | Poulsen HE, Specht E, Broedbaek K, Henriksen T, Ellervik C, Mandrup-Poulsen T, et al. RNA modifications by oxidation: a novel disease mechanism? Free Radic Biol Med 2012;52:1353-1361. DOI |
47 | Roszkowski K, Jozwicki W, Blaszczyk P, Mucha-Malecka A, Siomek A. Oxidative damage DNA: 8-oxoGua and 8-oxodG as molecular markers of cancer. Med Sci Monit 2011;17:CR329-CR333. |
48 | Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med (Berl) 1996;74:297-312. DOI |
49 | Borrego S, Vazquez A, Dasi F, Cerda C, Iradi A, Tormos C, et al. Oxidative stress and DNA damage in human gastric carcinoma: 8-oxo-7'8-dihydro-2'-deoxyguanosine (8-oxo-dG) as a possible tumor marker. Int J Mol Sci 2013;14:3467-3486. DOI |
50 | Chen Q, Hu Y, Fang Z, Ye M, Li J, Zhang S, et al. Elevated levels of oxidative nucleic acid modification markers in urine from gastric cancer patients: quantitative analysis by ultra performance liquid chromatography-tandem mass spectrometry. Front Chem 2020;8:606495. DOI |
51 | Kao HW, Pan CY, Lai CH, Wu CW, Fang WL, Huang KH, et al. Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer. Oncotarget 2017;8:56389-56397. DOI |
52 | Chan AW, Gill RS, Schiller D, Sawyer MB. Potential role of metabolomics in diagnosis and surveillance of gastric cancer. World J Gastroenterol 2014;20:12874-12882. DOI |
53 | Lai S. A human mode of intestinal type gastric carcinoma. Med Hypotheses 2019;123:27-29. DOI |
54 | Jayanthi VS, Das AB, Saxena U. Recent advances in biosensor development for the detection of cancer biomarkers. Biosens Bioelectron 2017;91:15-23. DOI |
55 | Abbas M, Habib M, Naveed M, Karthik K, Dhama K, Shi M, et al. The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice. Biomed Pharmacother 2017;95:1082-1090. DOI |
56 | Zhang T, Duran V, Vanarsa K, Mohan C. Targeted urine proteomics in lupus nephritis - a meta-analysis. Expert Rev Proteomics 2020;17:767-776. DOI |
57 | Chan AW, Mercier P, Schiller D, Bailey R, Robbins S, Eurich DT, et al. (1)H-NMR urinary metabolomic profiling for diagnosis of gastric cancer. Br J Cancer 2016;114:59-62. DOI |
58 | Jors A, Lund MA, Jespersen T, Hansen T, Poulsen HE, Holm JC. Urinary markers of nucleic acid oxidation increase with age, obesity and insulin resistance in Danish children and adolescents. Free Radic Biol Med 2020;155:81-86. DOI |
59 | Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0--the human metabolome database in 2013. Nucleic Acids Res 2013;41:D801-D807. |
60 | Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst (Lond) 2012;137:293-300. DOI |
61 | Jung J, Jung Y, Bang EJ, Cho SI, Jang YJ, Kwak JM, et al. Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolomic profiling. Ann Surg Oncol 2014;21 Suppl 4:S736-S742. |
62 | Chen JL, Fan J, Lu XJ. CE-MS based on moving reaction boundary method for urinary metabolomic analysis of gastric cancer patients. Electrophoresis 2014;35:1032-1039. DOI |
63 | Kwon HN, Lee H, Park JW, Kim YH, Park S, Kim JJ. Screening for early gastric cancer using a noninvasive urine metabolomics approach. Cancers (Basel) 2020;12:2904. DOI |
64 | Lyu J, Li H, Yin D, Zhao M, Sun Q, Guo M. Analysis of eight bile acids in urine of gastric cancer patients based on covalent organic framework enrichment coupled with liquid chromatography-tandem mass spectrometry. J Chromatogr A 2021;1653:462422. DOI |
65 | Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-383. DOI |
66 | Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. DOI |
67 | Njoku K, Chiasserini D, Jones ER, Barr CE, O'Flynn H, Whetton AD, et al. Urinary biomarkers and their potential for the non-invasive detection of endometrial cancer. Front Oncol 2020;10:559016. DOI |